Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 0.60 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3668318 | 0.90 | JAK2 (0.61) | JAK2JAK3KCNH2JAK1TYK2 | |
| SCHEMBL3671507 | 0.89 | JAK2 (0.58) | JAK2JAK3KCNH2JAK1TYK2 | |
| SCHEMBL3671195 | 0.86 | JAK2 (0.61) | JAK2JAK3KCNH2JAK1TYK2 | |
| SCHEMBL3679201 | 0.85 | JAK2 (0.58) | JAK2JAK3KCNH2 | |
| SCHEMBL3677577 | 0.83 | JAK2 (0.50) | JAK2JAK3KCNH2 | |
| SCHEMBL3512562 | 0.82 | JAK2 (0.62) | JAK2JAK3KCNH2JAK1TYK2 | |
| SCHEMBL3673068 | 0.82 | JAK2 (0.46) | JAK2JAK3KCNH2 | |
| SCHEMBL3675737 | 0.81 | JAK2 (0.56) | JAK2JAK3KCNH2 | |
| SCHEMBL3677146 | 0.78 | JAK2 (0.61) | JAK2JAK3KCNH2JAK1TYK2 | |
| SCHEMBL3674591 | 0.78 | JAK2 (0.58) | JAK2JAK3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |